The combined serplulimab and chemotherapy group provided a gain of 0.29 QALYs with incremental costs of $37,118.97 compared to the chemotherapy alone group for advanced ESCC patients with PD-L1 expression level of CPS≥10. Here, CD274 is linked to esophageal squamous cell carcinoma.